BackBetter Therapeutics- Tradeable Rights - March 2021 Overview

Better Therapeutics- Tradeable Rights - March 2021 Total Current Liabilities

Track Better Therapeutics- Tradeable Rights - March 2021's total current liabilities ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$12.94M
38.94% YoYΔ $3.63M vs prior year quarter

Peer average

Loading

Better Therapeutics- Tradeable Rights - March 2021 Total Current Liabilities History

Loading

Better Therapeutics- Tradeable Rights - March 2021 vs. peers: Total Current Liabilities Comparison

Loading

Better Therapeutics- Tradeable Rights - March 2021 Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) FAQ

Better Therapeutics- Tradeable Rights - March 2021's total current liabilities stands at $13M as of September 2023. That compares with $9.3M in the prior-year period — up 38.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Better Therapeutics- Tradeable Rights - March 2021 reported $13M in total current liabilities versus $9.3M a year earlier — a 38.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $9.3M in the prior-year period — up 38.9% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Better Therapeutics- Tradeable Rights - March 2021's total current liabilities evolved across reporting periods, while the comparison chart places MCADR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.